Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J.

Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1577414. [Epub ahead of print] No abstract available.

PMID:
30773115
2.

T-cell large granular lymphocyte leukemia transformation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.

Belhadj M, Mansour D, Kaltenbach S, Deau-Fischer B, Franchi P, Tamburini J, Chapuis N, Damotte D, Kosmider O, Burroni B, Bouscary D.

Haematologica. 2018 Dec 20. pii: haematol.2018.205542. doi: 10.3324/haematol.2018.205542. [Epub ahead of print]

3.

Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia.

Bories PN, Nakib S, Cynober L, Alary AS, Coude MM, Chevillon F, Tamburini J, Birsen R, Kosmider O, Bouscary D.

Clin Chem Lab Med. 2018 Sep 29. pii: /j/cclm.ahead-of-print/cclm-2018-0427/cclm-2018-0427.xml. doi: 10.1515/cclm-2018-0427. [Epub ahead of print] No abstract available.

PMID:
30267623
4.

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia.

Contejean A, Resche-Rigon M, Tamburini J, Alcantara M, Jardin F, Lengliné E, Adès L, Bouscary D, Marçais A, Lebon D, Chabrot C, Terriou L, Barraco F, Banos A, Bussot L, Cahn JY, Hirsch P, Maillard N, Simon L, Fornecker LM, Socié G, de Latour RP, de Fontbrune FS.

Haematologica. 2019 Feb;104(2):256-262. doi: 10.3324/haematol.2018.198440. Epub 2018 Sep 27.

5.

Nivolumab combined with ruxolitinib: antagonism or synergy?

Debureaux PE, Arrondeau J, Bouscary D, Goldwasser F.

Ann Oncol. 2018 May 1;29(5):1334-1335. doi: 10.1093/annonc/mdy077. No abstract available.

PMID:
29788168
6.

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, Pilorge S, Salah S, Quentin A, Deau B, Franchi P, Vignon M, Mabille L, Nguyen C, Kirova Y, Varlet P, Edjlali M, Dezamis E, Hoang-Xuan K, Soussain C, Houillier C, Damotte D, Pallud J, Bouscary D, Tamburini J.

Oncotarget. 2018 Mar 30;9(24):16822-16831. doi: 10.18632/oncotarget.24706. eCollection 2018 Mar 30.

7.

The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma.

Grignano E, Laurent J, Deau B, Burroni B, Bouscary D, Kirova YM.

Eur J Haematol. 2018 Apr 16. doi: 10.1111/ejh.13080. [Epub ahead of print]

PMID:
29660176
8.

[Renal toxicity of high-dose methotrexate].

Garcia H, Leblond V, Goldwasser F, Bouscary D, Raffoux E, Boissel N, Broutin S, Joly D.

Nephrol Ther. 2018 Apr;14 Suppl 1:S103-S113. doi: 10.1016/j.nephro.2018.02.015. French.

PMID:
29606256
9.

Radiotherapy of relapse-refractory follicular lymphoma.

Grignano É, Deau-Fischer B, Loganadane G, Breton M, Burroni B, Bouscary D, Kirova YM.

Cancer Radiother. 2018 Apr;22(2):126-130. doi: 10.1016/j.canrad.2017.09.003. Epub 2018 Feb 22.

PMID:
29477304
10.

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.

Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J.

Haematologica. 2018 Jul;103(7):e296-e299. doi: 10.3324/haematol.2017.185843. Epub 2018 Feb 22. No abstract available.

11.

Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study.

Bahuaud M, Bodilis H, Malphettes M, Maugard Landre A, Matondo C, Bouscary D, Batteux F, Launay O, Fermand JP.

Heliyon. 2017 Nov 6;3(11):e00441. doi: 10.1016/j.heliyon.2017.e00441. eCollection 2017 Nov.

12.

Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy.

Le Ray E, Belin L, Plancher C, Anract P, Babinet A, Dumaine V, Tamburini J, Deau Fischer B, Willems L, Magro L, Facon T, Leleu X, Bouscary D, Kirova YM.

Leuk Lymphoma. 2018 Jul;59(7):1756-1758. doi: 10.1080/10428194.2017.1393667. Epub 2017 Oct 31. No abstract available.

PMID:
29087212
13.

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.

Schlenk RF, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, Pabst T, Vusirikala M, Bouscary D, Spencer A, Candoni A, Gil JS, Berkowitz N, Weber HJ, Ottmann O.

Haematologica. 2018 Jan;103(1):e25-e28. doi: 10.3324/haematol.2017.172411. Epub 2017 Oct 19. No abstract available.

14.

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J.

Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15.

PMID:
28914261
15.

Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.

Chavarot N, Lebbe C, Thervet E, Bouscary D, Karras A.

Acta Derm Venereol. 2017 Oct 2;97(9):1138-1139. doi: 10.2340/00015555-2727.

16.

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.

Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, Bonmati C, Carré M, Couturier MA, Daguindau E, Marolleau JP, Orsini-Piocelle F, Delaunay J, Tavernier E, Lissandre S, Ojeda-Uribe M, Sanhes L, Sutton L, Banos A, Fornecker LM, Bernard M, Bouscary D, Saad A, Puyade M, Rouillé V, Luquet I, Béné MC, Hamel JF, Dreyfus F, Ifrah N, Pigneux A.

Blood Cancer J. 2017 Jun 2;7(6):e568. doi: 10.1038/bcj.2017.50. No abstract available.

17.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
18.

FLT3 inhibitors: clinical potential in acute myeloid leukemia.

Hospital MA, Green AS, Maciel TT, Moura IC, Leung AY, Bouscary D, Tamburini J.

Onco Targets Ther. 2017 Feb 3;10:607-615. doi: 10.2147/OTT.S103790. eCollection 2017. Review.

19.

Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation.

Bouscary D.

Ann Transl Med. 2016 Oct;4(Suppl 1):S53. No abstract available.

20.

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

Chesnais V, Arcangeli ML, Delette C, Rousseau A, Guermouche H, Lefevre C, Bondu S, Diop M, Cheok M, Chapuis N, Legros L, Raynaud S, Willems L, Bouscary D, Lauret E, Bernard OA, Kosmider O, Pflumio F, Fontenay M.

Blood. 2017 Jan 26;129(4):484-496. doi: 10.1182/blood-2016-03-707745. Epub 2016 Nov 16.

21.

Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.

Ohayon D, De Chiara A, Chapuis N, Candalh C, Mocek J, Ribeil JA, Haddaoui L, Ifrah N, Hermine O, Bouillaud F, Frachet P, Bouscary D, Witko-Sarsat V.

Sci Rep. 2016 Oct 19;6:35561. doi: 10.1038/srep35561.

22.

Anorexia nervosa hyperactivity-induced ischemic colitis (ANHIC): a new cause of anaemia.

Blanchet-Collet C, Sider A, Gal B, Hanachi-Guidoum M, Melchior JC, Bouscary D, Ringuenet D, de Tournemire R, Moro MR.

Eat Weight Disord. 2016 Sep;21(3):507-10. doi: 10.1007/s40519-016-0295-3. Epub 2016 Jun 17. No abstract available.

PMID:
27314583
23.

Acute myeloid leukaemia.

Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC.

Nat Rev Dis Primers. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. Review.

PMID:
27159408
24.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J.

Leuk Lymphoma. 2016 Dec;57(12):2820-2826. Epub 2016 Apr 27. Erratum in: Leuk Lymphoma. 2017 Feb;58(2):507-508.

25.

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J.

Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep.

26.

Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.

Adam K, Lambert M, Lestang E, Champenois G, Dusanter-Fourt I, Tamburini J, Bouscary D, Lacombe C, Zermati Y, Mayeux P.

Biosci Rep. 2015 Oct 23;35(6). pii: e00274. doi: 10.1042/BSR20150217.

27.

[Co-activation of AMPK and mTORC1: a therapeutic application of synthetic lethality in acute myeloid leukemia].

Tamburini J, Poulain L, Bouscary D, Sujobert P.

Med Sci (Paris). 2015 Oct;31(10):836-9. doi: 10.1051/medsci/20153110009. Epub 2015 Oct 19. French. No abstract available.

28.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17.

29.

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

Hunault-Berger M, Leguay T, Huguet F, Leprêtre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Béné MC, Liens D, Godfrin Y, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Am J Hematol. 2015 Sep;90(9):811-8. doi: 10.1002/ajh.24093.

30.

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decrooqc J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J.

Cell Rep. 2015 Jun 9;11(9):1446-57. doi: 10.1016/j.celrep.2015.04.063. Epub 2015 May 21.

31.

Targeting glutamine uptake in AML.

Jacque N, Bouscary D.

Oncoscience. 2014 Jan 10;1(1):1-2. eCollection 2014. No abstract available.

32.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C.

Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.

PMID:
25524177
33.

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.

Sarkozy C, Terré C, Jardin F, Radford I, Roche-Lestienne C, Penther D, Bastard C, Rigaudeau S, Pilorge S, Morschhauser F, Bouscary D, Delarue R, Farhat H, Rousselot P, Hermine O, Tilly H, Chevret S, Castaigne S.

Genes Chromosomes Cancer. 2014 Jan;53(1):106-16. doi: 10.1002/gcc.22123. Epub 2013 Oct 29.

PMID:
24249260
34.

Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.

Récher C, Béné MC, Lioure B, Pigneux A, Vey N, Delaunay J, Luquet I, Hunault M, Guyotat D, Bouscary D, Fegueux N, Jourdan E, Lissandre S, Escoffre-Barbe M, Bonmati C, Randriamalala E, Guièze R, Ojeda-Uribe M, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Guardiola P; Groupe Ouest-Est d’ étude des Leucé mies Aiguës et autres.

Leukemia. 2014 Feb;28(2):440-3. doi: 10.1038/leu.2013.290. Epub 2013 Oct 9. No abstract available.

PMID:
24166215
35.

Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.

Al-Nawakil C, Willems L, Mauprivez C, Laffy B, Benm'rad M, Tamburini J, Fontaine H, Sogni P, Terris B, Bouscary D, Moachon L.

Leuk Lymphoma. 2014 Jul;55(7):1670-4. doi: 10.3109/10428194.2013.845886. Epub 2013 Nov 14. No abstract available.

PMID:
24090500
36.

Chronic myelomonocytic leukemia associated with generalized myasthenia gravis.

Birsen R, Marcaud V, Omarjee L, Blanche P, Zuber M, Bouscary D, Tamburini J.

Leuk Lymphoma. 2014 Jul;55(7):1668-9. doi: 10.3109/10428194.2013.845296. Epub 2013 Nov 6. No abstract available.

PMID:
24050508
37.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6.

38.

Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.

Bertoli S, Bories P, Béné MC, Daliphard S, Lioure B, Pigneux A, Vey N, Delaunay J, Leymarie V, Luquet I, Blanchet O, Cornillet-Lefebvre P, Hunault M, Bouscary D, Fegueux N, Guardiola P, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Récher C; Groupe Ouest-Est d’Etude des Leucémies Aiguës et Autres Maladies du Sang (GOELAMS).

Haematologica. 2014 Jan;99(1):46-53. doi: 10.3324/haematol.2013.091819. Epub 2013 Aug 23.

39.

Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot.

Vignon C, Debeissat C, Georget MT, Bouscary D, Gyan E, Rosset P, Herault O.

PLoS One. 2013 Jul 30;8(7):e68425. doi: 10.1371/journal.pone.0068425. Print 2013.

40.

Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study.

Wiazzane N, Chargari C, Plancher C, Tamburini J, Asselain B, Fourquet A, Bouscary D, Kirova YM.

World J Radiol. 2013 Jun 28;5(6):248-52. doi: 10.4329/wjr.v5.i6.248.

41.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T.

J Clin Oncol. 2013 Aug 1;31(22):2806-9. doi: 10.1200/JCO.2012.46.2598. Epub 2013 Jun 24.

42.

Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support.

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Br J Haematol. 2013 Jun;161(5):738-40. doi: 10.1111/bjh.12284. Epub 2013 Mar 11. No abstract available.

PMID:
23480574
43.

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.

Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P, Cahn JY, Leguay T, Bories P, Witz F, Lamy T, Mayeux P, Lacombe C, Demur C, Tamburini J, Merlat A, Delepine R, Vey N, Dreyfus F, Béné MC, Ifrah N, Bouscary D; GOELAMS (Groupe Ouest Est d’Etude des Leucémies aiguës et Autres Maladies du Sang).

Leukemia. 2013 Jul;27(7):1479-86. doi: 10.1038/leu.2013.17. Epub 2013 Jan 16.

PMID:
23321953
44.

Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.

Kosmider O, Chapuis N, Kaltenbach S, Coriat R, Boudou Rouquette P, Willems L, Chesnais V, Radford-Weiss I, Bardet V, Mayeux P, Tamburini J, Fontenay M, Bouscary D.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):347-50. doi: 10.1016/j.clml.2012.11.007. No abstract available.

PMID:
23246161
45.

Large granular lymphocyte leukemia associated with hepatitis C virus infection and B cell lymphoma: improvement after antiviral therapy.

Poullot E, Bouscary D, Guyader D, Ghandour C, Roussel M, Fest T, Houot R, Lamy T.

Leuk Lymphoma. 2013 Aug;54(8):1797-9. doi: 10.3109/10428194.2012.752486. Epub 2012 Dec 26. No abstract available.

PMID:
23176408
46.

Neutrophilic myositis sine dermatitis in a neutropenic patient with myelodysplastic syndrome.

Mosnier E, Rousset P, Hugol D, Bouscary D, Aslangul E.

Ann Hematol. 2013 Apr;92(4):551-2. doi: 10.1007/s00277-012-1599-7. Epub 2012 Oct 13. No abstract available.

PMID:
23064893
47.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.

Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS.

Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22.

48.

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P.

J Clin Oncol. 2012 Jun 1;30(16):1949-52. doi: 10.1200/JCO.2011.36.5726. Epub 2012 Apr 30.

PMID:
22547600
49.

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction.

Descamps G, Gomez-Bougie P, Tamburini J, Green A, Bouscary D, Maïga S, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Br J Cancer. 2012 May 8;106(10):1660-7. doi: 10.1038/bjc.2012.139. Epub 2012 Apr 17.

50.

Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature.

Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N, Karras A, Salliot C, Suarez F, Avet-Loiseau H, Alyanakian MA, Nawakil CA, Park S, Tamburini J, Roux C, Bouscary D, Sparsa L.

Leuk Lymphoma. 2013 Apr;54(4):767-77. doi: 10.3109/10428194.2012.671481. Epub 2012 Apr 19. Review.

PMID:
22385269

Supplemental Content

Loading ...
Support Center